In vitro activity of ceftriaxone, cefetamet (Ro 15-8074), ceftetrame (Ro 19-5247; T-2588), and fleroxacin (Ro 23-6240; AM-833) versus Neisseria gonorrhoeae and Haemophilus ducreyi.
We examined 300 strains of Neisseria gonorrhoeae and 100 strains of Haemophilus ducreyi to determine their in vitro susceptibility to two new cephalosporins, cefetamet (Ro 15-8074) and ceftetrame (Ro 19-5247; T-2588), and a new fluroquinolone, fleroxacin (Ro 23-6240; AM-833). Their activity was compared with that of ceftriaxone, penicillin, spectinomycin, tetracycline, and erythromycin. Cefetamet, ceftetrame, and fleroxacin had excellent in vitro activity against both groups of microorganisms. beta-Lactamase production did not significantly affect the MICs of these agents. The Mtr phenotype of N. gonorrhoeae raised the MICs two- to fourfold, but the MICs remained within the range of achievable levels in serum. These newer compounds have a distinct advantage over existing therapeutic agents in that they can be administered orally. Clinical trials are warranted to assess their usefulness in the therapy of gonorrhea and chancroid.
D015281:Cefmenoxime / Q000031:analogs & derivatives*; D015296:Ceftizoxime / Q000031:analogs & derivatives*; D002443:Ceftriaxone / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D016576:Fleroxacin; D006191:Haemophilus ducreyi / Q000187:drug effects*; D006801:Humans; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D010406:Penicillins / Q000494:pharmacology; D000198:Spectinomycin / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology
D002511:Cephalosporins; D010406:Penicillins; C047444:cefetamet; D002939:Ciprofloxacin; D004917:Erythromycin; C049493:cefteram; D002443:Ceftriaxone; D000198:Spectinomycin; D015296:Ceftizoxime; D013752:Tetracycline; D015281:Cefmenoxime; D016576:Fleroxacin